Optimal timing maximises Paxlovid benefits for treating COVID-19
Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife.
The findings suggest that taking Paxlovid three to five days after COVID-19 symptoms emerge may maximise the drug’s ability to reduce viral loads, minimise viral spread and reduce viral rebound. They also indicate that broader use of Paxlovid during this window might be a powerful tool to help curb the spread of the SARS-CoV-2 ...













